Uta Bertsch

5.3k total citations
42 papers, 1.2k citations indexed

About

Uta Bertsch is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Uta Bertsch has authored 42 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 29 papers in Molecular Biology and 20 papers in Oncology. Recurrent topics in Uta Bertsch's work include Multiple Myeloma Research and Treatments (41 papers), Protein Degradation and Inhibitors (21 papers) and Cancer Treatment and Pharmacology (10 papers). Uta Bertsch is often cited by papers focused on Multiple Myeloma Research and Treatments (41 papers), Protein Degradation and Inhibitors (21 papers) and Cancer Treatment and Pharmacology (10 papers). Uta Bertsch collaborates with scholars based in Germany, France and United States. Uta Bertsch's co-authors include Hartmut Goldschmidt, Dirk Hose, Anna Jauch, Bronno van der Holt, Laila el Jarari, Henk M. Lokhorst, Pieter Sonneveld, Mark van Duin, Annemiek Broyl and Anja Seckinger and has published in prestigious journals such as Blood, PLoS ONE and Oncogene.

In The Last Decade

Uta Bertsch

37 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Uta Bertsch Germany 15 920 852 577 92 79 42 1.2k
Rowan Kuiper Netherlands 13 689 0.7× 629 0.7× 499 0.9× 76 0.8× 34 0.4× 36 920
Owen Stephens United States 13 541 0.6× 780 0.9× 515 0.9× 63 0.7× 197 2.5× 31 1.2k
Homare Eda United States 13 364 0.4× 815 1.0× 480 0.8× 62 0.7× 42 0.5× 29 1.0k
Jan Sterz Germany 14 394 0.4× 659 0.8× 412 0.7× 72 0.8× 85 1.1× 24 945
Ya‐Huei Kuo United States 15 357 0.4× 579 0.7× 235 0.4× 94 1.0× 114 1.4× 44 930
Marielle Chiron France 12 321 0.3× 299 0.4× 440 0.8× 81 0.9× 61 0.8× 44 745
Milada S. Vala United States 14 437 0.5× 349 0.4× 261 0.5× 177 1.9× 87 1.1× 20 860
Yuri Kamitsuji Japan 16 449 0.5× 369 0.4× 223 0.4× 294 3.2× 49 0.6× 32 929
Alberto Rocci Italy 14 373 0.4× 417 0.5× 170 0.3× 99 1.1× 87 1.1× 32 661
Lara Tickenbrock Germany 18 715 0.8× 1.0k 1.2× 229 0.4× 330 3.6× 138 1.7× 28 1.5k

Countries citing papers authored by Uta Bertsch

Since Specialization
Citations

This map shows the geographic impact of Uta Bertsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uta Bertsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uta Bertsch more than expected).

Fields of papers citing papers by Uta Bertsch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uta Bertsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uta Bertsch. The network helps show where Uta Bertsch may publish in the future.

Co-authorship network of co-authors of Uta Bertsch

This figure shows the co-authorship network connecting the top 25 collaborators of Uta Bertsch. A scholar is included among the top collaborators of Uta Bertsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uta Bertsch. Uta Bertsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Beck, Susanne, Vladimı́r Beneš, Hans Salwender, et al.. (2023). RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma. Frontiers in Immunology. 14. 1286700–1286700. 3 indexed citations
2.
Elias, K., Stefanie Huhn, Alexandra M. Poos, et al.. (2023). Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. Blood Cancer Journal. 13(1). 1–1. 20 indexed citations
3.
Seckinger, Anja, Michael Heider, Martina Rudelius, et al.. (2021). MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. Blood Advances. 6(2). 515–520. 7 indexed citations
4.
Sachpekidis, Christos, Maximilian Merz, Marc‐Steffen Raab, et al.. (2021). The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Research. 11(1). 100–100. 18 indexed citations
5.
Weinhold, Niels, Hans Salwender, David A. Cairns, et al.. (2021). Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. Haematologica. 106(10). 2754–2758. 53 indexed citations
6.
Kriegsmann, Katharina, Michael Hundemer, Sandra Sauer, et al.. (2020). Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. Cancers. 12(8). 2322–2322. 12 indexed citations
7.
Hose, Dirk, Susanne Beck, Hans Salwender, et al.. (2019). Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. Journal of Hematology & Oncology. 12(1). 65–65. 6 indexed citations
8.
Seckinger, Anja, Michael Heider, Ruth Eichner, et al.. (2019). MCT1 As Molecularly Validated Predictive Marker for Lenalidomide-Maintenance Therapy in Multiple Myeloma. Blood. 134(Supplement_1). 3187–3187. 1 indexed citations
9.
Chattopadhyay, Subhayan, Hauke Thomsen, Pankaj Yadav, et al.. (2019). Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma. Communications Biology. 2(1). 89–89. 9 indexed citations
10.
Merz, Maximilian, Anna Jauch, Thomas Hielscher, et al.. (2017). Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Advances. 2(1). 1–9. 22 indexed citations
11.
Engelhardt, Mélanie, Brigitte Neuber, Uta Bertsch, et al.. (2016). Lenalidomide enhances myeloma-specific T-cell responsesin vivoandin vitro. OncoImmunology. 5(5). e1139662–e1139662. 31 indexed citations
12.
Merz, Maximilian, Mathias Haenel, Uta Bertsch, et al.. (2015). Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma. Blood. 126(23). 4233–4233. 2 indexed citations
13.
Bøgsted, Martin, Anders Ellern Bilgrau, Christopher P. Wardell, et al.. (2013). Proof of the Concept to Use a Malignant B Cell Line Drug Screen Strategy for Identification and Weight of Melphalan Resistance Genes in Multiple Myeloma. PLoS ONE. 8(12). e83252–e83252. 9 indexed citations
14.
Moehler, Thomas, Anja Seckinger, Dirk Hose, et al.. (2013). The Glycome of Normal and Malignant Plasma Cells. PLoS ONE. 8(12). e83719–e83719. 13 indexed citations
15.
Broyl, Annemiek, Rowan Kuiper, Mark van Duin, et al.. (2012). Relation Between Cereblon Expression and Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Thalidomide. Blood. 120(21). 3973–3973.
16.
Schmitt, Stefan, Uta Bertsch, & Hartmut Goldschmidt. (2010). Experiences with bortezomib in multiple myeloma – from Phase II studies to daily practice. International Journal of Clinical Pharmacology and Therapeutics. 48(7). 494–496.
17.
Broyl, Annemiek, Sophie L. Corthals, Joost L.M. Jongen, et al.. (2010). Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. The Lancet Oncology. 11(11). 1057–1065. 173 indexed citations
18.
19.
Seckinger, Anja, Tobias Meißner, Jérôme Moreaux, et al.. (2009). Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene. 28(44). 3866–3879. 62 indexed citations
20.
Hose, Dirk, Anja Seckinger, Hartmut Goldschmidt, et al.. (2009). Inhibition of HIF1A Signaling by a Novel Class of Sulfonanilides for Targeted Treatment of Multiple Myeloma.. Blood. 114(22). 2856–2856. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rowan Kuiper Breakdown of academic impact, for papers by Owen Stephens Breakdown of academic impact, for papers by Homare Eda Breakdown of academic impact, for papers by Jan Sterz Breakdown of academic impact, for papers by Ya‐Huei Kuo Breakdown of academic impact, for papers by Marielle Chiron Breakdown of academic impact, for papers by Milada S. Vala Breakdown of academic impact, for papers by Yuri Kamitsuji Breakdown of academic impact, for papers by Alberto Rocci Breakdown of academic impact, for papers by Lara Tickenbrock
Rankless by CCL
2026